Visceral obesity is a better predictor than generalized obesity for basal insulin requirement at the initiation of insulin therapy in patients with type 2 diabetes
Introduction
Body weight or obesity is a commonly used determinant to assess the amount of insulin required at the initiation of insulin therapy in patients with type 2 diabetes. The initial amount of basal insulin required is known to range from 0.4 to 0.5 units/kg body weight per day [1]. However, the insulin dose determined based on body weight is frequently outside the optimal dosage range, and this may result in unexpected hypoglycemia and/or hyperglycemia [2]. Moreover, the bedtime insulin dose required to achieve reasonable glycemic control varies 20-fold, from 8 to 170 units/day [3], [4].
The insulin requirement depends on endogenous insulin secretion, insulin sensitivity, the amount of insulin absorbed, and other factors such as anti-insulin antibodies [4]. Among these, inter-individual variation in insulin sensitivity seems to be a major factor. Ryysy et al. [4] reported that hepatic fat content and insulin action on free fatty acids and glucose metabolism, rather than insulin absorption, are associated with the insulin requirement during insulin therapy in patients with type 2 diabetes. In addition, central or visceral obesity is strongly associated with insulin resistance. Hayashi et al. [5] demonstrated that visceral adiposity, not abdominal subcutaneous fat area, was associated with an increase in future insulin resistance. However, there has been no study regarding the association between visceral obesity and insulin requirement in type 2 diabetes.
In this study, we aimed to identify clinical parameters influencing inter-individual variation in basal insulin requirement in insulin-naïve patients with type 2 diabetes. To predict basal insulin requirement, we used an overnight insulin infusion algorithm with some modifications [6], [7].
Section snippets
Study subjects
Fifty consecutive patients with type 2 diabetes, in whom conventional outpatient treatment with either diet or any combination of oral antidiabetic agents had failed, were referred to the inpatient diabetes service. All study patients were hospitalized only for glycemic control. The inclusion criteria for patients in this study were age 20–75 years, a diagnosis of type 2 diabetes, poor glycemic control (glycated hemoglobin; HbA1C > 8.0% [63.9 mmol/mol]), and not on insulin therapy. The exclusion
Clinical characteristics of study subjects
The clinical characteristics of the diabetic patients are summarized in Table 2. The mean age was 56.7 ± 15.3 years, and the mean duration of diabetes was 9.0 ± 7.3 years. The mean HbA1C was 10.4 ± 1.4% (90.7 ± 15.7 mmol/mol). The mean BMI was 26.1 ± 4.8 kg/m2. Forty-one patients (82%) were treated with sulfonylurea, 33 (66%) with metformin, and 4 (8%) with thiazolidinedione. Seven patients were on diet and exercise alone.
Blood glucose changes and insulin dose administered during the 8 h overnight insulin infusion
The mean blood glucose at 22:00 h was 17.3 ± 4.9 mmol/L. The mean blood glucose
Discussion
In our study, visceral fat area was a significant predictor of basal insulin requirement at the initiation of insulin therapy in patients with type 2 diabetes. However, body weight, waist circumference, total body fat, or subcutaneous fat area were not associated with basal insulin requirement.
It is often difficult for clinicians to determine the amount of insulin required when they start insulin therapy in insulin-naïve patients with type 2 diabetes. The estimation of insulin dose based on
Conflict of interest
The authors declare that they have no conflict of interest.
References (21)
- et al.
Effects of outcome on in-hospital transition from intravenous insulin infusion to subcutaneous therapy
Am J Cardiol
(2006) - et al.
Conversion of intravenous insulin infusions to subcutaneously administered insulin glargine in patients with hyperglycemia
Endocr Pract
(2006) - et al.
NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome
Hepatology
(2002) - et al.
Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial)
Diabetes Care
(2007) - et al.
Insulin requirements in 242 patients with type II diabetes mellitus
Endocr Pract
(1995) - et al.
Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial
Ann Intern Med
(1999) - et al.
Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients
Diabetes
(2000) - et al.
Visceral adiposity, not abdominal subcutaneous fat area, is associated with an increase in future insulin resistance in Japanese Americans
Diabetes
(2008) - et al.
An overnight insulin infusion algorithm provides morning normoglycemia and can be used to predict insulin requirements in noninsulin-dependent diabetes mellitus
J Clin Endocrinol Metab
(1997) - et al.
Techniques for the measurement of visceral fat: a practical guide
Int J Obes Relat Metab Disord
(1993)
Cited by (11)
Insulin requirement profiles of short-term intensive insulin therapy in patients with newly diagnosed type 2 diabetes and its association with long-term glycemic remission
2015, Diabetes Research and Clinical PracticeCitation Excerpt :Son et al. also reported a decrease of visceral fat after early intensive insulin therapy in type 2 diabetes [6]. Increased proportion of visceral fat is known to increase basal insulin requirement [26]. Third, although prolonged administration of insulin increases body weight [27], lifestyle modification in this study resulted in a slight decrease of body weight, thereby potentially improving insulin sensitivity.
Seasonal variation in visceral fat and blood HbA1c in people with type 2 diabetes
2012, Diabetes Research and Clinical PracticeLong-chain SFA at the sn-1, 3 positions of TAG reduce body fat deposition in C57BL/6 mice
2013, British Journal of NutritionThe impact of phenotype, ethnicity and genotype on progression of type 2 diabetes mellitus
2020, Endocrinology, Diabetes and MetabolismGender-related affecting factors of prediabetes on its 10-year outcome
2016, BMJ Open Diabetes Research and Care